ClinicalTrials.gov
ClinicalTrials.gov Menu

ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00709527
Recruitment Status : Completed
First Posted : July 3, 2008
Last Update Posted : June 18, 2012
Sponsor:
Information provided by (Responsible Party):
Ophthotech Corporation

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : March 2011
  Actual Study Completion Date : March 2011